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ACIP Recommendations:
Polio and Polio Vaccines
 First outbreak described in the U.S. in 
1843
Polio epidemics were reported each 
summer and fall
More than 21,000 paralytic cases 
reported in the U.S. in 1952
Poliomyelitis Disease
Three serotypes of wild poliovirus: 
– WPV1
– WPV2
– WPV3
Minimal heterotypic immunity between serotypes
Rapidly inactivated by heat, chlorine, formaldehyde, and 
ultraviolet light
Poliovirus
 Enters into mouth
 Replicates in pharynx and GI tract
 Hematologic spread to lymphatics and 
central nervous system
 Viral spread along nerve fibers
 Destruction of motor neurons
Poliomyelitis Pathogenesis
Racaniello VR. One hundred years of poliovirus pathogenesis. Virology 2006;344:9-16
Outcomes of Poliovirus Infection
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illness
Aseptic meningitis Flaccid paralysis
Asymmetric paralysis 
 Reservoir Human
 Transmission Fecal-oralOral-oral possible
 Communicability Most infectious: 7–10 days before onset Virus present in stool 3–6 weeks
Poliovirus Epidemiology
Poliomyelitis—United States, 1950–2011
Source: National Notifiable Disease Surveillance System, CDC 
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VAPP Imported
Poliomyelitis—United States, 1980–2010
Vaccine –associated paralytic polio = VAPP
1955–Inactivated vaccine 
1963–Live, attenuated vaccine (OPV)
1987–Enhanced-potency, inactivated                           
vaccine (IPV)
Poliovirus Vaccines
Highly effective in producing immunity to poliovirus
– ≥90% of recipients immune after 2 doses
– ≥99% of recipients immune after 3 doses
Duration of immunity not known with certainty
Enhanced Inactivated Polio Vaccine
Polio-Containing Vaccine Products 
Product
ACIP Abbreviation Age Indications  IPV Series 
IPOL
IPV 6 weeks and older Any dose in the series 
Pediarix
DTaP-IPV-HepB 6 weeks through 6 years Doses 1 through 3 
Pentacel
DTaP-IPV/Hib 6 weeks through 4 years Doses 1 through 4 
Kinrix
DTaP-IPV 4 through 6 years Dose 4 
Quadracel
DTaP-IPV 4 through 6 years Dose 4 or 5 
IPV Dose  Routinely Recommended Age  
1 2 months
2 4 months 
3 6–18 months 
4 4–6 years 
ACIP Polio Immunization Recommendations 
Routine Childhood Schedule 
 Infants 6 months of age and younger, follow the 
recommended schedule intervals 
 If accelerated protection is needed (e.g., travel to polio-
endemic area), minimum age and intervals may be followed
ACIP Polio Immunization Recommendations 
Catch-Up Schedule  
Dose Minimum Age Minimum Interval to the Next Dose 
Dose 1 6 weeks 4 weeks 
Dose 2 10 weeks 4 weeks 
Dose 3 14 weeks 6 months 
Dose 4 4 years -----------
A 4th dose is not necessary if the 3rd dose was administered:
– At age 4 years or older AND 
– At least 6 months after the previous dose
Children who have received 4 doses (or more) before 4 years 
of age need an additional dose
– There should be at least 6 months between last and next-to-last dose 
ACIP Polio Immunization Recommendations 
4th Dose and the Catch-Up Schedule
Mixed-product series containing both OPV and IPV is 
acceptable 
– Only trivalent OPV (tOPV) counts toward completing the series
Children with an incomplete series: 
– Administer IPV to complete a series that includes doses of OPV
– Ensure doses met minimum ages and intervals 
Administer 1 dose of IPV to children who received 4 doses of 
OPV (or more) before 4 years of age
– There should be at least 6 months the last dose of OPV and the IPV 
dose 
Schedules that Include Both IPV and OPV
Use the date of administration to make a presumptive 
determination of what type of OPV was received
Trivalent OPV was used throughout the world prior to        
April 2016
Persons 18 years of age and younger with doses of OPV that 
do not count towards the U.S. vaccination requirements 
should receive IPV
OPV Administered Outside the U.S. 
Routine vaccination of U.S. residents 18 years of age or older 
is not necessary or recommended
May consider vaccination of travelers to polio-endemic 
countries and selected lab workers 
ACIP Polio Immunization Recommendations 
Adolescents and Adults
Use routine IPV schedule if possible 
– 0, 1–2 months, 6–12  months intervals
 If accelerated protection is needed (e.g., travel to polio-
endemic area), use the minimum intervals 
ACIP Polio Immunization Recommendations 
Unvaccinated Adults 
Minimum Intervals to the Next Dose
Dose 1 4 weeks 
Dose 2 6 months 
Dose 3 --------------
Previously completed series
– Administer 1 dose of IPV to those at risk
 Incomplete series
– Administer remaining doses in series based on immunization history
– No need to restart a valid, documented series 
• Valid = minimum intervals met 
ACIP Polio Immunization Recommendations 
Previously Vaccinated Adults
Contraindication
– Severe allergic reaction to a vaccine component or following a prior 
dose of vaccine
Precaution
– Moderate to severe acute illness 
Contraindications and Precautions 
 Local reactions 2.8% (pain, redness, swelling)
 Severe reactions rare
IPV Adverse Reactions
 Last case in the United States in 1979
Western Hemisphere certified polio-free in 1994
 Last isolate of WPV2 was in India in October 1999
Global eradication goal 
Polio Eradication 
Global Polio Eradication Initiative
 Storage: Refrigerate between 2°C and 8°C (36°F and 46°F)
 Preparation: Prepare the vaccine just prior to administration 
– Pentacel requires reconstitution
– Reconstitute the lyophilized vaccine with the DTaP-IPV liquid diluent 
supplied by the manufacturer. Do NOT use Kinrix or Quadracel
 Route: IM injection*
 Site:  
– 11 months and younger: Anterolateral thigh muscle
– 12 months and older: Anterolateral thigh muscle or deltoid muscle of arm
 Needle:
– Children: 22–25 gauge, 1-inch needle 
– Adults: 22–25 gauge, length varies by weight
Clinical Considerations for IPV-Containing Vaccines 
*iPV may be administered by subcutaneous injection using a 5/8-inch needle given in the fatty tissue over the upper, outter triceps or anterolateral thigh 
 Schedule errors: Dose 4 administered too soon 
– Doses administered 5 or more days before the minimum age and/or interval 
do not count and should be repeated when age-appropriate  
– Wait the minimum interval from the invalid dose before giving the repeat 
dose 
– Minimum age/interval: At/after age 4 AND 6 months after dose 3 
 Age/dose errors: Kinrix or Quadracel for doses 1 through 3
– If the minimum age and interval from the last dose of polio vaccine has been 
met, the dose can count and does not need to be repeated  
 Preparation errors: Wrong diluent to reconstitute DTaP-IPV/Hib 
(Pentacel) 
– Do not use Kinrix or Quadracel to reconstitute Pentacel
Polio: Vaccine Administration Errors 
ACIP Recommendations: 
Haemophilus influenzae type b and Hib Vaccine
National Center for Immunization & Respiratory Diseases
Immunization Services Division
Severe bacterial infection, particularly among infants
Aerobic gram-negative bacteria
Polysaccharide capsule 
6 different serotypes (a–f) of polysaccharide capsule
95% of invasive disease caused by type b (prevaccine era)
Haemophilus influenzae type b
 Formerly the leading cause of bacterial meningitis among 
children younger than 5 years of age
Approximately 1 in 200 children developed invasive Hib 
disease
Almost all infections among children younger than 5 years
Impact of Haemophilus influenzae type b Disease
Haemophilus influenzae type b
Clinical Manifestations*
*Prevaccine era
Bacteremia
2%
Cellulitis
6%
Arthritis
8%
Osteomyelitis
2%
Pneumonia
15%
Epiglottitis
17%
Meningitis
50%
Facial cellulitis or infection of the soft tissues of the face, caused by Hib
 Reservoir Human asymptomatic carriers
 Transmission Respiratory droplets presumed
 Temporal pattern Peaks in Sept. through Dec. and March through May 
 Communicability Generally limited but higher in some circumstances (e.g., household, child care)
Haemophilus influenzae type b Epidemiology
Estimated Annual Incidence (per 100,000) of Invasive Haemophilus influenzae
type b (Hib) Disease in Children Aged <5 Years—U.S., 1980–2012
MMWR 2014;63(RR1):1–14 
Haemophilus influenzae, Invasive Disease Incidence of Reported Cases 
(per 100,000), by serotype Among Children aged <5 years—U.S., 2000–2013
MMWR 2015;62(53):1–119
0.27 per 100,000 
Healthy People 2020 Goal
Available 1985–1988 
Not effective in children younger than 18 months of age 
Efficacy in older children varied 
Age-dependent immune response 
Not consistently immunogenic in children 2 years of age and 
younger 
No booster response 
Haemophilus influenzae type b Polysaccharide Vaccine 
Conjugation improves immunogenicity
– Immune response with booster doses
Same polysaccharide capsule linked to different carrier 
proteins
3 single-component conjugate Hib vaccine products 
1 combination vaccine products available that contain Hib 
conjugate vaccine
Haemophilus influenzae Type b Conjugate Vaccines
Hib-Containing Vaccine Products 
ACIP Hib Immunization Recommendations 
Routine Schedule 
*Minimum age for the 1st dose is 6 weeks
Routinely recommended for all infants beginning at 2 months 
of age*
Schedule varies based on the product used 
– ActHib, Pentacel, Hiberix: Follow the 4-dose schedule at 2, 4, 6, and         
12–15 months of age 
– PedvaxHIB: Follow the 3-dose schedule at 2, 4, and 12–15 months of 
age 
 If any dose in the series is ActHIB, Pentacel, Hiberix or the 
product is not known, follow the 4-dose schedule 
 Children starting late may not 
need entire 3- or 4-dose series 
 Number of doses child requires 
depends on current age
 Resources: 
– 2018 catch-up schedule
– Catch-up guidance for healthy 
children 
– Detailed schedule p. 128 of Pink Book
Unvaccinated Healthy Children 7 months of Age and Older 
Catch-Up Guidance for Healthy Children 4 Months through 4 Years of Age  www.cdc.gov/vaccines/schedules/downloads/child/job-aids/hib-actHib.pdf
Generally not recommended for healthy persons older than 59 
months of age
Vaccinate high-risk older children and adolescents if 
incompletely or previously unvaccinated  
• Asplenia
• Immunodeficiency 
• HIV infection
• Receipt of chemotherapy or radiation therapy 
ACIP Hib Immunization Recommendations 
Older Children and Adults
High-Risk Children and Adults Hib Vaccine Guidance
Elective splenectomy If unvaccinated: 1 dose prior to procedure
Asplenic patient If unvaccinated: 1 dose
HIV-infected children If unvaccinated: 1 dose
Hematopoietic cell transplant 3 doses (at least 4 weeks apart) beginning 6–12 months after transplant
HIV-infected adults Hib vaccination is not recommended
ACIP Hib Immunization Recommendations 
High-Risk Children and Adults
 “Unvaccinated” means someone who meets both criteria:
Less than the routine series through 14 months;
AND
No doses after 14 months of age
“Unvaccinated” and High-Risk Catch-Up
Children less than 24 months of age with invasive Hib disease
– Administer complete series as recommended for child’s age
– Vaccinate during the convalescent phase of the illness
American Indian/Alaska natives
– Hib disease peaks earlier in infancy
– PedVaxHIB vaccine produces protective antibody after first dose/early 
protection 
– PedVaxHIB vaccine is specifically recommended for primary series 
doses
Special Populations
 All single-component conjugate Hib vaccines are interchangeable 
for primary series and booster dose
 3-dose primary series (4 doses total) if more than one brand of 
vaccine used at 2 or 4 months of age
 Whenever feasible, use same combination vaccine for subsequent 
doses
 If vaccine used for earlier doses is not known or not available, any 
brand may be used to complete the series
Hib Vaccine Interchangeability
Severe allergic reaction to vaccine component or following 
previous dose
Moderate to severe acute illness
Age younger than 6 weeks
Contraindications and Precautions
Swelling, redness, or pain in 5–30% of recipients
Systemic reactions infrequent
Serious adverse reactions rare
Hib Vaccine Adverse Reactions
 Storage: Refrigerate between 2°C and 8°C 
(36°F and 46°F)
 Preparation: Prepare vaccine just prior to 
administration 
– ActHIB, Pentacel, and Hiberix require reconstitution
– Reconstitute the lyophilized vaccine with the diluent 
supplied by the manufacturer
 Route: IM injection
 Site:  
– 11 months and younger: Anterolateral thigh muscle
– 12 months and older: Anterolateral thigh muscle or 
deltoid muscle of arm
 Needle: 22–25 gauge, 1-inch needle 
Clinical Considerations for Hib-Containing Vaccine 
 Preparation errors: Using the wrong diluent to reconstitute the 
lyophilized component 
Hib: Vaccine Administration Errors 
CDC vaccine storage label examples https://www.cdc.gov/vaccines/hcp/admin/storage/guide/vaccine-storage-labels.pdf
 Provide the polio and Hib vaccine 
information statement (VIS) when a 
combination vaccine is administered 
– There are no VISs specific for Kinrix, 
Pediarix, Pentacel, or Quadracel
 Other option: multiple vaccines VIS 
– May be used in place of the individual VISs 
for DTaP, Hib, hepatitis B, polio, and PCV13 
when two or more of these vaccines are 
administered during the same visit
– It may be used for infants through children 
receiving their routine 4- to 6-year vaccines
Additional 
Clinical Considerations 
CDC vaccine information statements  www.cdc.gov/vaccines/hcp/vis/vis-statements/multi.html
 Resources and references are 
available on the webinar web 
page 
Polio and Vaccine Resources and References 
